Full-Time

Clinical Sales Specialist

CS

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Compensation Overview

$140k - $155k/yr

Senior

Houston, TX, USA

Required to travel up to 100% of the time, including up to 40% overnight travel.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • BA/BS or equivalent work experience
  • 5+ years sales experience required
  • recent endocrine relationships, specialty therapeutic, hospital, or orphan drugs sales experience highly preferred
Responsibilities
  • Build and develop professional relationships with influential high prescribers and thought leaders in the territory to enhance Corcept brand and product loyalty
  • Leverages expertise and knowledge of the therapeutic disease state, the marketplace, applicable competitors, industry, and cross-functional activities/plans to anticipate and effectively manage business opportunities and challenges
  • Develops and implements effective customer specific territory plans and communicates insights to internal stakeholders
  • Prioritizes time and effort to ensure optimal coverage of appropriate physician specialists based on opportunity and potential
  • Plan and participate in education programs and speaker dinner programs
  • Manage territory expenses/budget to support sales and marketing activities
Desired Qualifications
  • Proven track record of consistent high performance
  • Strong ability to collaborate and work cross-functionally
  • Required to travel up to 100% of the time, including up to 40% overnight travel
  • Must maintain a driving record in accordance with Corcept vehicle policy
  • Able to lift and/or move up to 35 pounds

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is an FDA-approved medication for Cushing's syndrome, a condition caused by excessive cortisol. Corcept stands out from competitors by having discovered over 1,000 selective cortisol modulators and by heavily investing in research and development to create new treatments. The company's goal is to expand its product offerings while also providing educational resources to improve patient care and understanding of cortisol-related disorders.

Company Size

201-500

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Corcept's stock is the best performing pharma stock in 2025.
  • The MOMENTUM trial could expand Corcept's market reach.
  • Recent investments show growing confidence in Corcept's future prospects.

What critics are saying

  • Securities fraud investigations could lead to legal and financial repercussions.
  • Teva's antitrust lawsuit may result in legal challenges.
  • Potential reputation damage from ongoing legal investigations.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

4%

2 year growth

-1%
Access News Wire
Mar 18th, 2025
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.

Stock Titan
Mar 10th, 2025
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.

PR Newswire
Mar 3rd, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Insider Monkey
Feb 23rd, 2025
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 30th, 2024
Corcept files NDA for new Cushing's syndrome drug

Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.